How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?   

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic? 

What are symptoms to be monitoring for and how is it typically diagnosed?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Rocky Mountain Cancer Centers
It's a challenging topic, and we need more informa...
Medical Oncologist at University of Texas MD Anderson Cancer Center
The reported incidence of ILD is high. Therefore, ...
Medical Oncologist at Arizona Hem/Onc
I prefer to do pre-treatment PFTs and just let pat...
Medical Oncologist at Southwest Medcl Consult SC
All my patients routinely keep a daily drug log, t...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution